CAMP4 specializes in treatments that target regRNAs, forms of RNA that regulate the expression of nearby protein-encoding genes and have not been explored as therapeutic targets. RegRNAs are within what scientists often call the “dark side” of the genome— the 98% of the human genome that does not encode proteins . . .
The post Mountain Climbing: CAMP4 Aims to Scale the Heights of Disease appeared first on GEN – Genetic Engineering and Biotechnology News.